North Chicago biotech startup BLR Bio has received U.S. Food & Drug Administration Orphan Drug Designation for its investigational treatment for the rare disease systemic sclerosis. The drug, BLR-200, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback